CQ Pharmaceutical shareholders approve Q1-Q3 profit distribution plan

CQ Pharmaceutical Holding Company Limited announced the successful approval of its 2025 first three quarters profit distribution plan at the fifth extraordinary general meeting of shareholders held on December 22, 2025. The meeting, which combined on-site and online voting, saw 524 shareholders representing 1,019,346,801 shares, or 59.5142% of the total voting shares, participate.

The primary resolution, the "2025 First Three Quarters Profit Distribution Plan," was passed with 1,018,537,601 votes in favor, representing 99.9206% of the effective voting shares. There were 722,300 votes against (0.0709%) and 86,900 abstentions (0.0085%). Among small and medium investors, the plan received 98.8785% approval.

The company's board of directors convened the meeting, which complied with all relevant laws, regulations, and the company's articles of association. Beijing Jingtian & Gongcheng Law Firm provided a legal opinion, affirming the legality and validity of the meeting's convening, procedures, and resolutions.